Shamburg News · 8-K filed Nov 12, 2026, 8:00 AM EST
CorMedix Reports Third Quarter 2026 Net Loss of $14.7 Million on $54.5 Million Revenue
CRMD · CorMedix Inc.
- Earnings
- Acquisition
- Financing
- Other event
- Materiality: high
CorMedix Inc. reported financial results for the quarter ended September 30, 2026, with total revenue and grant income of $54.5 million and a net loss of $14.7 million, or $(0.19) per basic and diluted share. Adjusted EBITDA was $3.1 million, and the company maintained full-year 2026 consolidated revenue guidance of $325 to $345 million while narrowing its adjusted EBITDA guidance to $130 to $140 million. The company also announced a definitive asset purchase agreement to acquire substantially all of the assets of Heron Therapeutics and suspended previously issued 2027 DefenCath revenue guidance.
Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001410098-26-000063.
Written from the filing by Shamburg Markets. Figures are as reported by the company.